Detalhe da pesquisa
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
2.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
3.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904798
4.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
5.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
6.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
7.
Cryoglobulinemic Vasculitis in Disguise: Cryofibrinogenemia as Variant of Monoclonal Gammopathy of Renal Significance.
Am J Kidney Dis
; 83(3): 415-419, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37734685
8.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717583
9.
Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study.
J Proteome Res
; 22(9): 3022-3028, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499263
10.
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.
Haematologica
; 108(4): 1105-1114, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770529
11.
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.
Hematol Oncol
; 2023 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37458281
12.
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Am J Hematol
; 98(5): 750-759, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866925
13.
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(27): 1823-1840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492991
14.
Conditional relative survival in Waldenström's macroglobulinaemia: a population-based study in The Netherlands.
Br J Haematol
; 196(5): 1205-1208, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738239
15.
Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
Br J Haematol
; 196(3): 660-669, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605017
16.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet
; 398(10299): 491-502, 2021 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097852
17.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
18.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
19.
IgM monoclonal gammopathies of clinical significance: diagnosis and management.
Haematologica
; 107(9): 2037-2050, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770530
20.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006